Expanding the Reach of Precision Medicine

Expanding the Reach of Precision Medicine

Publication date: Nov 07, 2019

Dr. Bruce Johnson, Chief Clinical Research Officer from the Dana Farber Cancer Institute, joins us to discuss how recent advances in treating rare cancers can help drive the understanding and expansion of precision medicine.

Concepts Keywords
Anaplastic Social media
Beer Cancer care
Biomarker Relatively unusual tumors
Biopsy Advanced disease
Bradford Rare cancers
Caf Clinical cancer
Cancer Common tumor
Chemotherapy Aplastic lymphoma
Chicago Patient’s tumor
Chris Dodd Colon cancer
Chronic Disease Small tumors
Clinical Trials Melanoma
Colon Patient centered cancer
Dana Farber Patients tumors
Dog Appropriate tumors
Egypt Different tumors
Elk Melanomas
Embolism Anaplastic thyroid cancers
Emp Chronic disease
FDA Particular diseases
Gene Tumor’s
Genome Positive urine cancer
Giraffe Desmond tumors
Hospital Rare tumors
Immunotherapy Chemotherapy
Ing Immunotherapy
Inhibitor Medicine
Jae Seo Clinical medicine
Jerome Health
Kettering Lung cancer
Lung RTT
Lung Cancer Biotechnology
Lymphoma Foundation Medicine
Mab Dana–Farber Cancer Institute
Madison Small-cell carcinoma
Melanoma Personalized medicine
Melanomas Chemotherapy
Motrin
Mutants
Mutation
Nib
Oncologist
Patient Centered Care
Pdo
Pimple
Plastic
Podcast
Precision Medicine
Prognosis
Receptor
Sequencing
Smoked
Social Media
Synovial
Talking Therapies
Tarceva
Targeted Therapy
Targeted Treatments
Thyroid
Thyroid Cancer
Toxicity
Tumor
Tumor Suppressor
Twitter
Urine

Semantics

Type Source Name
gene UNIPROT BIRC6
disease MESH Cancer
disease DOID Cancer

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *